- Home
- VIGL vs ASRT Comparison
VIGL vs ASRT Comparison
Compare VIGL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- ASRT
- Stock Information
- Founded
- VIGL 2020
- ASRT 1995
- Country
- VIGL United States
- ASRT United States
- Employees
- VIGL N/A
- ASRT N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- ASRT Health Care
- Exchange
- VIGL Nasdaq
- ASRT Nasdaq
- Market Cap
- VIGL 125.3M
- ASRT 123.9M
- IPO Year
- VIGL 2022
- ASRT 1997
- Fundamental
- Price
- VIGL $3.44
- ASRT $1.10
- Analyst Decision
- VIGL Buy
- ASRT Strong Buy
- Analyst Count
- VIGL 5
- ASRT 5
- Target Price
- VIGL $16.60
- ASRT $3.35
- AVG Volume (30 Days)
- VIGL 95.5K
- ASRT 446.9K
- Earning Date
- VIGL 11-05-2024
- ASRT 11-06-2024
- Dividend Yield
- VIGL N/A
- ASRT N/A
- EPS Growth
- VIGL N/A
- ASRT N/A
- EPS
- VIGL N/A
- ASRT N/A
- Revenue
- VIGL N/A
- ASRT $132,186,000.00
- Revenue This Year
- VIGL N/A
- ASRT N/A
- Revenue Next Year
- VIGL N/A
- ASRT $4.68
- P/E Ratio
- VIGL N/A
- ASRT N/A
- Revenue Growth
- VIGL N/A
- ASRT N/A
- 52 Week Low
- VIGL $2.47
- ASRT $0.73
- 52 Week High
- VIGL $9.24
- ASRT $2.60
- Technical
- Relative Strength Index (RSI)
- VIGL 50.31
- ASRT 39.53
- Support Level
- VIGL $3.32
- ASRT $1.15
- Resistance Level
- VIGL $3.60
- ASRT $1.25
- Average True Range (ATR)
- VIGL 0.18
- ASRT 0.06
- MACD
- VIGL 0.02
- ASRT -0.01
- Stochastic Oscillator
- VIGL 63.31
- ASRT 3.57
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.